HbA1c Testing Market Size & Growth Forecast 2027–2036, By Segments (End-use, Technology, Type of Device), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to Content
Market Size and Growth Outlook
HbA1c Testing Market size was more than USD 2.6 billion in 2026 and is set to grow at a 6.94% CAGR between 2027 and 2036, reaching USD 5.09 billion by 2036. The industry revenue for 2027 is calculated at USD 2.75 billion.
Get more details on this report
Request Free Sample ReportHbA1c Testing Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 45.75% market share in 2026, supported by routine diabetes screening, established laboratory infrastructure, and consistent integration of HbA1c testing into long-term disease management.
- Asia Pacific is projected to expand at a 10.4% CAGR as diabetes testing demand rises, healthcare access improves, and more patients enter routine monitoring and early detection programs.
Segment Momentum
- Hospitals & Clinics held a 43.86% share in 2026 because they manage high testing volumes for diabetes diagnosis, monitoring, and treatment within established clinical care pathways.
- High-Performance Liquid Chromatography is the fastest-growing technology as healthcare providers increasingly prioritize reliable analytical performance for ongoing diabetes management.
Market Expansion Drivers
- Increasing global diabetes prevalence driving demand for routine HbA1c testing.
- Adoption of point-of-care HbA1c devices improving clinical workflow efficiency.
- Rising obesity and aging populations increasing long-term glycemic monitoring needs.
Leading Market Participants
- Major companies in the HbA1c testing market include Abbott Laboratories (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Bio-Rad Laboratories, Inc. (United States), Tosoh Corporation (Japan), ARKRAY, Inc. (Japan), Trinity Biotech plc (Ireland), Danaher Corporation (United States), Sekisui Medical Co., Ltd. (Japan), Menarini Diagnostics S.r.l. (Italy).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 2.6 billion
- 2027 Estimated Market Size: USD 2.75 billion.
- Projected Market Size: USD 5.09 billion by 2036
- Growth Forecast: 6.94% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Hospitals & Clinics (End-use) | Immunoassays (Technology) | Laboratory-based Testing Devices (Type of Device)
- Emerging Opportunity Segment: Homecare Settings (End-use) | High-Performance Liquid Chromatography (Technology) | Point-of-care (POC)Testing Devices (Type of Device)
Market Growth Drivers and Industry Trends
Increasing global diabetes prevalence driving demand for routine HbA1c testing
The HbA1c testing market will benefit from the growing global prevalence of diabetes, which is increasing the need for regular assessment of long-term blood glucose control. Routine testing supports ongoing disease monitoring and enables clinicians to evaluate glycemic management over time, strengthening demand across diabetes care settings.
Adoption of point-of-care HbA1c devices improving clinical workflow efficiency
Adoption of point-of-care HbA1c devices is improving clinical workflow efficiency by enabling testing closer to the patient and supporting faster access to results. The HbA1c testing market is gaining from this shift as healthcare providers seek more streamlined testing processes that can facilitate timely assessment and treatment decisions.
Rising obesity and aging populations increasing long-term glycemic monitoring needs
Growing obesity levels and aging populations are expanding the need for sustained glycemic monitoring, supporting the HbA1c testing market as healthcare systems manage patients requiring ongoing assessment. These demographic and lifestyle trends increase the relevance of regular HbA1c evaluation within longer-term diabetes management practices.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing global diabetes prevalence driving demand for routine HbA1c testing | 2.20% | High | North America, Asia Pacific | High | Near Term |
| Adoption of point-of-care HbA1c devices improving clinical workflow efficiency | 2.00% | High | North America, Europe | High | Near Term |
| Rising obesity and aging populations increasing long-term glycemic monitoring needs | 1.60% | Moderate | Asia Pacific, Europe | High | Mid Term |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
North America dominated the HbA1c testing market, accounting for a 45.75% share in 2026, supported by the region's established diabetes screening and management infrastructure and strong adoption of laboratory and point-of-care diagnostic technologies. High awareness of diabetes prevention and long-term disease monitoring encourages regular HbA1c testing among diagnosed patients as well as individuals at elevated risk. The presence of well-developed healthcare systems, favorable reimbursement environments, and routine integration of HbA1c testing into clinical workflows further reinforces demand. In addition, growing emphasis on preventive healthcare and the management of diabetes-related complications is sustaining the use of HbA1c testing across hospitals, diagnostic laboratories, and outpatient care settings.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is positioned as the fastest-growing regional market, driven by the expanding burden of diabetes, improving access to healthcare services, and increasing awareness of early diagnosis and continuous glucose management. Healthcare infrastructure development across emerging economies is enabling wider availability of diagnostic testing, while the expansion of hospitals, clinics, and laboratory networks is improving access beyond major urban centers. Greater adoption of automated and point-of-care testing technologies is also helping providers deliver HbA1c testing more efficiently. Rising healthcare expenditure, increasing screening initiatives, and a growing focus on chronic disease management are expected to support sustained market expansion as diabetes care becomes more integrated into routine healthcare practices.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants / StartupsiScaleSparseModerate Dense | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
Germany 🇩🇪
Standardized Diabetes ManagementGermany is emphasizing HbA1c testing as a core component of structured diabetes care and disease monitoring programs. Demand is driven by the need for reliable testing platforms that support consistent treatment evaluation and patient management.
France 🇫🇷
Preventive Diabetes CareFrance is encouraging wider use of HbA1c testing to strengthen preventive strategies and improve management of patients at risk of diabetes complications. Laboratories are focusing on accurate and efficient testing services that support routine monitoring.
Italy 🇮🇹
Chronic Disease MonitoringItaly is integrating HbA1c testing more deeply into chronic disease management pathways as diabetes prevalence places greater demand on healthcare services. Providers are prioritizing dependable testing technologies that facilitate regular patient assessment and treatment adjustment.
Japan 🇯🇵
Aging Population ScreeningJapan is strengthening the use of HbA1c testing to address the growing burden of age-related diabetes and metabolic disorders. Healthcare providers are integrating regular testing into preventive care and long-term disease management frameworks.
South Korea 🇰🇷
Decentralized Testing AdoptionSouth Korea is increasing adoption of HbA1c testing in outpatient and community settings to improve early diabetes detection and monitoring. The market favors convenient diagnostic solutions that support efficient chronic disease management programs.
United States 🇺🇸
Diabetes Monitoring ExpansionThe U.S. continues to expand HbA1c testing across hospitals, diagnostic laboratories, and community care settings to improve diabetes management. Providers are prioritizing accessible and rapid testing solutions that support long-term patient monitoring and preventive care strategies.
HbA1c Testing Market Share (%), by End-use, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportEnd-use Segment Analysis: Hospitals & Clinics (Largest Segment) vs Homecare Settings (Fastest-Growing Segment)
Hospitals & clinics dominated the HbA1c testing market with a 43.86% share in 2026, owing to their central role in diabetes diagnosis, routine monitoring, and treatment management. These facilities benefit from established laboratory infrastructure and trained healthcare professionals capable of integrating HbA1c testing into broader clinical workflows. The growing need for regular glycemic assessment, particularly among patients requiring ongoing diabetes management, supports consistent testing demand across hospitals and outpatient clinics while the emphasis on timely clinical decision-making reinforces the segment's strong position.
Homecare settings are expected to experience the fastest growth as diabetes management increasingly shifts toward convenient and patient-centered monitoring. Home-based HbA1c testing can reduce dependence on frequent healthcare visits while supporting patients in tracking long-term glycemic control within their daily routines. Greater awareness of preventive diabetes management, expanding access to user-friendly testing technologies, and the broader movement toward decentralized healthcare are encouraging adoption in homecare environments.
Technology Segment Analysis: Immunoassays (Largest Segment) vs High-Performance Liquid Chromatography (Fastest-Growing Segment)
Immunoassays held the largest share of the HbA1c testing market at 37.51% in 2026, supported by their established presence in clinical laboratories and their suitability for routine HbA1c measurement. Their integration into commonly used diagnostic workflows enables efficient testing and consistent monitoring across healthcare settings. Continued demand for accessible and dependable diabetes diagnostics, together with the need for high-throughput testing in established clinical environments, is sustaining the widespread use of immunoassay-based approaches.
High-performance liquid chromatography is advancing rapidly as laboratories place greater emphasis on analytical accuracy, reliable separation of hemoglobin variants, and dependable HbA1c measurement. The technology's ability to provide detailed analytical performance makes it valuable for settings where precise characterization is important for clinical interpretation. Increasing sophistication of laboratory diagnostics and continued efforts to improve the reliability of diabetes testing are supporting broader adoption of high-performance liquid chromatography.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| End-use | Hospitals & Clinics, Diagnostic Laboratories, Homecare Settings | Hospitals & Clinics | Homecare Settings |
| Technology | Immunoassays, Chromatography, Enzymatic Assays, Boronate Affinity Chromatography, High-Performance Liquid Chromatography, Others | Immunoassays | High-Performance Liquid Chromatography |
| Type of Device | Laboratory-based Testing Devices, Point-of-care (POC)Testing Devices | Laboratory-based Testing Devices | Point-of-care (POC)Testing Devices |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Top players in the HbA1c testing market:
1. Abbott Laboratories (United States)
2. F. Hoffmann-La Roche Ltd. (Switzerland)
3. Siemens Healthineers AG (Germany)
4. Bio-Rad Laboratories Inc. (United States)
5. Tosoh Corporation (Japan)
6. ARKRAY Inc. (Japan)
7. Trinity Biotech plc (Ireland)
8. Danaher Corporation (United States)
9. Sekisui Medical Co. Ltd. (Japan)
10. Menarini Diagnostics S.r.l. (Italy)
Increasing emphasis on diabetes management is accelerating innovation in the HbA1c testing market, with manufacturers introducing automated analyzers, point-of-care diagnostic systems, and high-accuracy testing technologies that improve patient monitoring and clinical workflow efficiency.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories (United States) | |||||||
| F. Hoffmann-La Roche Ltd. (Switzerland) | |||||||
| Siemens Healthineers AG (Germany) | |||||||
| Bio-Rad Laboratories Inc. (United States) | |||||||
| Tosoh Corporation (Japan) | |||||||
| ARKRAY Inc. (Japan) | |||||||
| Trinity Biotech plc (Ireland) | |||||||
| Danaher Corporation (United States) | |||||||
| Sekisui Medical Co. Ltd. (Japan) | |||||||
| Menarini Diagnostics S.r.l. (Italy). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Orange Biomed | Mar-25 | Orange Biomed introduced an at-home HbA1c testing solution designed to enable accurate diabetes monitoring from a small blood sample. The system leverages microfluidics and single-cell analysis to improve accessibility and decentralize glycemic control tracking, supporting the shift toward patient-centric diagnostic models and expanding home-based chronic disease management capabilities. |
| FIND / Abbott / i-SENS / Siemens Healthineers | Apr-23 | FIND partnered with Abbott, i-SENS Inc, and Siemens Healthineers to provide discounted point-of-care HbA1c test kits for low- and middle-income countries. The initiative aims to improve diabetes diagnosis and monitoring accessibility in underserved regions by expanding availability of affordable diagnostic tools across decentralized healthcare settings. |
| LumiraDx | Nov-22 | LumiraDx expanded the commercial reach of its HbA1c testing platform, enabling broader adoption across multiple care settings. The system delivers rapid results for diabetes screening and monitoring, supporting improved clinical decision-making and strengthening point-of-care diagnostic capabilities in decentralized healthcare environments. |
| Labcorp | May-22 | Labcorp introduced an at-home diabetes risk testing kit using a home collection device developed by Weavr Health. The solution enhances accessibility to diagnostic services by enabling remote sample collection and supports the broader shift toward home-based screening and preventive care in diabetes management. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
HbA1c Testing Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Sample Type | Whole Blood, Capillary Blood, Venous Blood |
| Purchasing Model | Direct Procurement, Distributor-Mediated Procurement, Group Purchasing Organization (GPO) Procurement, Contract-Based Procurement |
| Testing Frequency | Routine Screening, Quarterly Monitoring, Biannual Monitoring, Annual Monitoring, High-Frequency Monitoring |
HbA1c Testing Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Point-of-Care Testing Adoption Pathways |
|
| Diagnostic Access Expansion Opportunities |
|
| Clinical Workflow Integration Strategies |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
What is the current revenue of the HbA1c testing market?
What is the forecasted size of the HbA1c testing industry?
How is point-of-care HbA1c testing changing procurement and clinical workflow priorities?
What factors are sustaining long-term demand for HbA1c testing across healthcare systems?
Why do hospitals and clinics lead the HbA1c testing market?
Which technology segment is growing the fastest in the HbA1c testing market?
Why does North America dominate the HbA1c testing market?
What is fueling HbA1c testing market growth in Asia Pacific?
Which companies are driving growth in the HbA1c testing landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook